Arctic Bioscience AS
Research Arctic Bioscience AS (ABS) on Bullrun: market cap NOK 75.21M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABS
- ExchangeOL
- CountryNorway
- SectorHealthcare
- IndustryBiotechnology
- CurrencyNOK
- Market capNOK 75.21M
- Financial periodQ1 2026
- RevenueNOK 130.32M
- Net incomeNOK 43.01M
- Free cash flowNOK 37.86M
- Gross margin48.0%
Valuation Snapshot
latest market cap is NOK 75.21M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | NOK 43.48M | -NOK 47.93M | -NOK 96.17M | 27.3% | -1.89 | NOK 2.16M | NOK 32.86M | NOK 210.73M |
| FY2023 | NOK 33.75M | -NOK 45.51M | -NOK 65.07M | 29.0% | -1.79 | NOK 78.47M | NOK 5.58M | NOK 258.56M |
| FY2022 | NOK 34.27M | -NOK 34.02M | -NOK 83.96M | 34.0% | -1.39 | NOK 143.16M | NOK 1.10M | NOK 287.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-14 | NOK 75.21M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 NOK.
About Arctic Bioscience AS
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Arctic Bioscience AS's market cap?
Arctic Bioscience AS's market capitalization is NOK 75.21M.
What does Arctic Bioscience AS do?
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial. It also sells nutraceuticals as an intermediary and finished goods products under the ROMEGA brand name.